Subcutaneous bortezomib in multiple myeloma patients induces similar therapeutic response rates as intravenous application but it does not reduce the incidence of peripheral neuropathy.
Minarik J, Pavlicek P, Pour L, Pika T, Maisnar V, Spicka I, Jarkovsky J, Krejci M, Bacovsky J, Radocha J, Straub J, Kessler P, Wrobel M, Walterova L, Sykora M, Obernauerova J, Brozova L, Gregora E, Adamova D, Gumulec J, Adam Z, Scudla V, Hajek R; Czech Myeloma Group.
Minarik J, et al. Among authors: adam z.
PLoS One. 2015 Apr 14;10(4):e0123866. doi: 10.1371/journal.pone.0123866. eCollection 2015.
PLoS One. 2015.
PMID: 25875484
Free PMC article.